Therapeutic dendrimer

Provided herein are dendrimers comprising: a core unit, five generations of building units which are lysine residues or analogues thereof, first terminal groups comprising a cabazitazel residue covalently attached to a diglycolyl linker group, and second terminal groups comprising a PEG group. Also...

Full description

Saved in:
Bibliographic Details
Main Authors Owen, David James, Edmondson, Stephanie Ruth, Fairley, Jacinth, Kelly, Brian Devlin, Main, Nicola Jane, Paull, Jeremy Robert Arthur
Format Patent
LanguageEnglish
Published 27.08.2024
Subjects
CHEMISTRY
COMPOSITIONS BASED THEREON
HUMAN NECESSITIES
HYGIENE
MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONSONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC MACROMOLECULAR COMPOUNDS
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
THEIR PREPARATION OR CHEMICAL WORKING-UP
Online AccessGet full text

Cover

More Information
Summary:Provided herein are dendrimers comprising: a core unit, five generations of building units which are lysine residues or analogues thereof, first terminal groups comprising a cabazitazel residue covalently attached to a diglycolyl linker group, and second terminal groups comprising a PEG group. Also provided herein are pharmaceutical compositions comprising the dendrimers, and methods and uses of the dendrimers in therapy of disorders such as cancers. Processes for making the dendrimers and intermediates are also provided.
Bibliography:Application Number: US202117461655